BioSpace News Archive

Positive liver cancer detection data published in Cancer Discovery demonstrates the promise of Delfi Diagnostics’ high-performance, accessible liquid biopsy platform in a new tumor type.

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

The Native Antigen Company (part of LGC Clinical Diagnostics) today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

Cassava Sciences, Inc. announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offering.

Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced it is planning an interim analysis of at least 25% of the patients for the KALAHARI Phase 2, Part B clinical trial.

aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 13,200 shares of its common stock, each with an exercise price of $2.38 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on November 16, 2022, the effective date of the grants.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical” or the “Company”) today announced its financial results and provided a business update for the six months ended June 30, 2022.

Regulatory News: Lysogene announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license.

Apellis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).